¼¼°èÀÇ À¯À×À°Á¾ ½ÃÀå
Ewing Sarcoma
»óǰÄÚµå : 1757565
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 377 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,053,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,161,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ À¯À×À°Á¾ ½ÃÀåÀº 2030³â±îÁö 8¾ï 2,900¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 6¾ï 3,500¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ À¯À×À°Á¾ ½ÃÀåÀº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 4.5%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 8¾ï 2,900¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ º´¿ë¿ä¹ýÀº CAGR 5.4%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 5¾ï 5,840¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ´Üµ¶¿ä¹ý ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 3.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 7,300¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ À¯À×À°Á¾ ½ÃÀåÀº 2024³â¿¡ 1¾ï 7,300¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 1¾ï 7,330¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 8.4%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 1.8%¿Í 3.6%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ À¯À×À°Á¾ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¿µ»ó Áø´ÜÀÇ ¹ßÀüÀº À¯À×À°Á¾ÀÇ Àü¸ÁÀ» ¾î¶»°Ô ¹Ù²Ü °ÍÀΰ¡?

À¯À×À°Á¾ ½ÃÀåÀº Áø´Ü ´É·Â¿¡ ÀÖÀ¸¸ç, »ó´çÇÑ ÁøÈ­¸¦ ÀÌ·ç¾úÀ¸¸ç, ¿µ»ó ±â¼úÀº Áúº´ÀÇ ¹ß°ß, º´±â °áÁ¤ ¹× ÁøÇà ¸ð´ÏÅ͸µ¿¡ ÀÖÀ¸¸ç, ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¾çÀüÀÚ¹æ»ç¼±´ÜÃþÃÔ¿µ(PET), ÀÚ±â°ø¸í¿µ»ó(MRI), ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ(CT)Àº À¯À×À°Á¾°ú ´Ù¸¥ ¼Ò¿øÇü¼¼Æ÷Á¾°úÀÇ °¨º°¿¡ µµ¿òÀÌ µÇ°í ÀÖÀ¸¸ç, MRI´Â ³ôÀº °ø°£Àû ÇØ»óµµ·Î ÀÎÇØ ƯÈ÷ °ñ¹Ý ¹× Ãà»è°ñ°Ý°ú °°Àº ºÎÀ§ÀÇ ¿ø¹ß¼º Á¾¾çÀ» Æò°¡Çϱâ À§ÇÑ ¿µ»ó Áø´Ü¹ýÀ¸·Î ¼±Åõǰí ÀÖ½À´Ï´Ù. µÇ¾ú½À´Ï´Ù. ÃÖ±Ù¿¡´Â È®»ê°­Á¶ MRI¿Í µ¿ÀûÁ¶¿µ¿µ»óÀ¸·Î Ä¡·á È¿°úÀÇ Æò°¡°¡ °³¼±µÇ¾î Á¶±â °³ÀÔ°ú Ä¡·áÀÇ ¼öÁ¤ÀÌ ¿ëÀÌÇØÁ³½À´Ï´Ù.

ÀÌ¿Í ÇÔ²² ÀΰøÁö´É(AI) ±â¹Ý ¿µ»ó ºÐ¼® Ç÷§ÆûÀÌ È®»êµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ç÷§ÆûÀº º´¿ø Áø´Ü ½Ã½ºÅÛ¿¡ ÅëÇյǾî Á¾¾ç ´Ü¸éÀÇ ¹¦»ç¿Í ÀüÀÌ º´º¯ÀÇ ½Äº° Á¤È®µµ¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÅøÀº Á¾¾çÀÌ Á¾Á¾ Æó³ª °ñ¼ö·Î Á¶±â ÀüÀ̵Ǵ °æ¿ì°¡ ¸¹´Ù´Â Á¡À» °í·ÁÇÒ ¶§ ƯÈ÷ Áß¿äÇÕ´Ï´Ù. ¹æ»ç¼±Çаú À¯ÀüüÇÐÀÇ À¶ÇÕ ¶ÇÇÑ À¯¸ÁÇϸç, ÀÌ ÁúȯÀÇ Æ¯Â¡ÀûÀÎ À¯ÀüÀû ¡ÈÄÀÎ EWSR1 ÀüÁ¸¦ ¿¹ÃøÇÒ ¼ö ÀÖ´Â ¸ðµ¨ÀÌ µîÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áø´ÜÀÇ ¹ßÀüÀº Á¶±â ¹ß°ß°ú °èÃþÈ­µÈ Ä¡·á °áÁ¤À» ÃËÁøÇÏ°í ±Ã±ØÀûÀ¸·Î ¿¹Èĸ¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù.

À¯À×À°Á¾ Ä¡·á ÆÄÀÌÇÁ¶óÀÎ Çü¼º¿¡¼­ ºÐÀÚÇ¥ÀûÄ¡·áÁ¦´Â ¾î¶² ¿ªÇÒÀ» ÇÒ ¼ö Àִ°¡?

À¯À×À°Á¾¿¡ ´ëÇÑ ÀüÅëÀûÀÎ Ä¡·á Á¢±Ù¹ýÀº ¿À·§µ¿¾È È­Çпä¹ý, ¼ö¼ú, ¹æ»ç¼± Ä¡·áÀÇ Á¶ÇÕÀ» Áß½ÉÀ¸·Î Àü°³µÇ¾î ¿Ô½À´Ï´Ù. ±×·¯³ª Àç¹ß ¶Ç´Â ÀüÀ̼º Áúȯ¿¡ ´ëÇÑ »ýÁ¸À²ÀÌ Á¤Ã¼µÊ¿¡ µû¶ó °³¹ß ÆÄÀÌÇÁ¶óÀÎÀº ºÐÀÚ Ç¥Àû ¹× ¸é¿ªÄ¡·á Àü·«À¸·Î Á¡Á¡ ´õ À̵¿Çϰí ÀÖ½À´Ï´Ù. ÇöÀç, EWS-FLI1 Àü»ç ÀÎÀÚ(EWSR1 À¯ÀüÀÚÀÇ Àç¹è¿­·Î ÀÎÇÑ À¶ÇÕ ¾Ï ´Ü¹éÁú)ÀÇ È°¼ºÀ» ¾ïÁ¦ÇÏ´Â »õ·Î¿î ¾à¹°ÀÌ ¼³°èµÇ°í ÀÖÀ¸¸ç, RNA Ç︮ĿÁ¦ A, LSD1 ¹× EZH2¿Í °°Àº ÈļºÀ¯ÀüÇÐÀû Á¶Àý ÀÎÀÚ¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â ÀúºÐÀÚ ¾ïÁ¦Á¦´Â ¾Ï À¯¹ß ÀüÀÌ ÇÁ·Î±×·¥À» Á÷Á¢ÀûÀ¸·Î ¾ïÁ¦ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Ãʱ⠴ܰèÀÇ ÀÓ»ó½ÃÇèÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ ¸é¿ªÄ¡·á Á¢±Ù¹ýµµ º´ÇàµÇ°í ÀÖÀ¸¸ç, ƯÈ÷ CD99¿Í °°Àº Ç¥¸é ´Ü¹éÁúÀ» Ç¥ÀûÀ¸·Î ÇÏ´Â TCR-T ¼¼Æ÷³ª CAR-T ¼¼Æ÷¿Í °°Àº Àΰø T ¼¼Æ÷ Ä¡·áÁ¦ÀÇ °³¹ßÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. Á¾¾ç ¹Ì¼¼È¯°æÀÇ ¸é¿ª¾ïÁ¦ ¹®Á¦´Â üũÆ÷ÀÎÆ® ¾ïÁ¦Á¦¿Í »çÀÌÅäÄ«ÀÎ Á¶ÀýÁ¦¸¦ Æ÷ÇÔÇÑ º´¿ë¿ä¹ýÀ¸·Î ÇØ°áµÇ°í ÀÖ½À´Ï´Ù. ÀÌÁ߯¯À̼ºÇ×ü ¹× ¾Ï ¹é½Åµµ ÇöÀç ¿¬±¸ ÁßÀ̸ç, ÀϺΠÃʱ⠴ܰèÀÇ Èĺ¸¹°ÁúÀº ³­Ä¡¼º ȯÀÚ¿¡¼­ Áúº´À» ¾ÈÁ¤È­½ÃŰ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á Çõ½ÅÀº ƯÈ÷ ¿¬±¸±â°ü°ú ¾Ï ºÐ¾ß »ý¸í°øÇÐ ±â¾÷ °£ÀÇ Çù·ÂÀÌ °­È­µÊ¿¡ µû¶ó ÀüÀÓ»ó °³³ä Áõ¸í¿¡¼­ ÀÓ»ó Àû¿ëÀ¸·Î Á¡Â÷ ÀüȯµÇ°í ÀÖ½À´Ï´Ù.

Àü ¼¼°è À¯À×À°Á¾ Ä¡·á »ýŰè´Â Áö¿ªº°·Î ¾î¶»°Ô ÁøÈ­Çϰí Àִ°¡?

¼¼°è À¯À×À°Á¾ Ä¡·á ȯ°æÀº ÀÇ·á ÀÎÇÁ¶ó, Á¾¾çÇÐ Áø´Ü¿¡ ´ëÇÑ Á¢±Ù¼º, Èñ±ÍÁúȯ Ä¡·á¸¦ À§ÇÑ Àڱݿ¡ µû¶ó Å©°Ô ´Þ¶óÁý´Ï´Ù. ºÏ¹Ì¿Í ¼­À¯·´°ú °°Àº °í¼Òµæ Áö¿ª¿¡¼­´Â Á¾ÇÕÀûÀÎ ´ÙÇÐÁ¦Àû Ä¡·á¿Í ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ ºñ±³Àû Àß °®Ãß¾îÁ® ÀÖ½À´Ï´Ù. À°Á¾ Àü¹®¼¾ÅÍ¿¡¼­´Â °í±Þ À¯Àüü ½ÃÄö½Ì°ú ´ÙÁ¦ º´¿ë Ä¡·á ¿ä¹ýÀÌ Á¦°øµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¾´ÜÀû ȯÀÚ µî·Ï ¹× ¹ÙÀÌ¿À¹ðÅ©ÀÇ µ¥ÀÌÅÍ´Â ¸ÂÃã Ä¡·á Àü·«°ú Ä¡·á ÈÄ ¸ð´ÏÅ͸µÀ» °³¼±ÇÏ´Â µ¥ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù.

¹Ý¸é, ¾Æ½Ã¾ÆÅÂÆò¾ç°ú ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ½ÅÈï ±¹°¡µéÀº Á¶±â Áø´Ü, Ä¡·áÀÇ °¡¿ë¼º, ÁöÁö¿ä¹ý ¼­ºñ½º¿¡¼­ °ÝÂ÷¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ºÐÀÚ»ý¹°ÇÐÀû Áø´Ü¿¡ ´ëÇÑ Á¢±Ù¼º Áö¿¬Àº Á¾Á¾ ÁøÇà ´Ü°èÀÇ ¹ß°ßÀ¸·Î À̾îÁ® »ýÁ¸ °á°ú¿¡ ¾Ç¿µÇâÀ» ¹ÌĨ´Ï´Ù. ±×·¯³ª °øÁߺ¸°Ç ÇÁ·Î±×·¥°ú ±¹Á¦ Çù·ÂÀ» ÅëÇØ ÀÌ·¯ÇÑ °ÝÂ÷´Â Á¡Â÷ ÇØ¼ÒµÇ°í ÀÖ½À´Ï´Ù. Àεµ³ª ºê¶óÁú°ú °°Àº ±¹°¡ÀÇ Ä¡·á ±â°üµéÀº ±¹Á¦ °øµ¿ ÀÓ»ó½ÃÇè¿¡ Âü¿©Çϰí Ç¥ÁØÈ­µÈ Ä¡·á ÇÁ·ÎÅäÄÝÀ» äÅÃÇϰí ÀÖ½À´Ï´Ù. ÈÞ´ë¿ë ¿µ»ó Áø´Ü ¼Ö·ç¼Ç°ú Ŭ¶ó¿ìµå ±â¹Ý ÀÇ·áÁ¤º¸ÇÐÀº ³óÃÌ Áö¿ªÀ¸·ÎÀÇ Á¢±Ù¼ºÀ» °³¼±Çϱâ À§ÇØ È°¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ³ë·ÂÀº Èñ±Í ¼Ò¾Æ¾ÏÀÌ ¼¼°è º¸°ÇÀÇ ÃÖ¿ì¼± °úÁ¦¶ó´Â ÀνÄÀÌ È®»êµÇ°í ÀÖÀ½À» ¹Ý¿µÇÕ´Ï´Ù.

À¯À×À°Á¾ ½ÃÀåÀÇ ¸ð¸àÅÒÀ» °¡¼ÓÈ­ÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?

À¯À×À°Á¾ ½ÃÀåÀÇ ¼ºÀåÀº ¿µ»ó ¹× ºÐÀÚÁø´Ü ±â¼ú ¹ßÀü, À¶ÇÕ ´Ü¹éÁúÀ» Ç¥ÀûÀ¸·Î ÇÏ´Â ÁøÇà ÁßÀÎ ÀǾàǰ °³¹ß ÆÄÀÌÇÁ¶óÀÎ, º¸´Ù °ß°íÇÑ ÀÓ»ó½ÃÇè »ýÅÂ°è µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ ƯÁ¤ Áö¿ª¿¡¼­´Â ¼Ò¾Æ ¹× û¼Ò³â °ñÀ°Á¾ ¹ß»ý·üÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, Á¶±â °ËÁø ¹× Àü¹® Ä¡·á ÀÎÇÁ¶ó¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. Èñ±Í ¼Ò¾Æ¾Ï¿¡ ´ëÇÑ ¿ËÈ£ Ȱµ¿°ú ÀÚ±Ý Áö¿ø Áõ°¡´Â ÀǾàǰ Çõ½ÅÀ» ÃËÁøÇϰí ÀÖÀ¸¸ç, Èñ±ÍÁúȯ Ä¡·áÁ¦ ÁöÁ¤Àº ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú »ó¾÷Àû Ÿ´ç¼ºÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

¶Ç ´Ù¸¥ Å« ¿øµ¿·ÂÀº Çаè, »ý¸í°øÇÐ ½ºÅ¸Æ®¾÷, ¼¼°è ¾Ï ÄÁ¼Ò½Ã¾ö °£ÀÇ Çù·Â °ü°èÀÇ È®´ëÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ³×Æ®¿öÅ©´Â ½Ç½Ã°£ µ¥ÀÌÅÍ °øÀ¯, »ý¹°ÇÐÀû ½Ã·á ±³È¯, ´Ù±â°ü ÀÓ»ó½ÃÇèÀ» °¡´ÉÇÏ°Ô ÇÏ¿© ½Å¾àÀÇ ¿¬±¸ºÎÅÍ ½ÃÀå Ãâ½Ã±îÁö °É¸®´Â ½Ã°£À» ´ÜÃàÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ µðÁöÅÐ º´¸®, ÀüÀÚÀǹ«±â·Ï, AI ±â¹Ý ¿¹ÈÄ ¿¹Ãø ÅøÀÇ Ã¤ÅÃÀº ÀÓ»óÀû ÀÇ»ç°áÁ¤À» °£¼ÒÈ­ÇÏ°í °á°ú¿¡ ±â¹ÝÇÑ Ä¡·á °èȹÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Á¤¹Ð Á¾¾çÇÐÀÌ Èñ±Í¾Ï °ü¸®ÀÇ Áß½ÉÀÌ µÇ¸é¼­ ÅëÇÕ Ä¡·á ¸ðµ¨°ú »ý¹°ÇÐÀû Á¤º¸¿¡ ±â¹ÝÇÑ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä´Â Áö¼ÓÀûÀ¸·Î È®´ëµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â À¯À×À°Á¾ ¼Ö·ç¼ÇÀÇ Àü¹ÝÀûÀÎ ½ÃÀå Àü¸Á¿¡ Ȱ·ÂÀ» ºÒ¾î³Ö°í ÀÖ½À´Ï´Ù.

ºÎ¹®

Ä¡·á À¯Çü(º´¿ë¿ä¹ý, ´Üµ¶¿ä¹ý); Áø´Ü À¯Çü(MRI ½ºÄµ, CT ½ºÄµ, Ç÷¾×°Ë»ç, °ñ¼ö »ý°Ë); ÃÖÁ¾»ç¿ëÀÚ(º´¿ø ÃÖÁ¾»ç¿ëÀÚ, Àü¹® Ŭ¸®´Ð ÃÖÁ¾»ç¿ëÀÚ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ 44»ç)

AI ÅëÇÕ

¿ì¸®´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Ewing Sarcoma Market to Reach US$829.0 Million by 2030

The global market for Ewing Sarcoma estimated at US$635.0 Million in the year 2024, is expected to reach US$829.0 Million by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Combination Therapy, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$558.4 Million by the end of the analysis period. Growth in the Monotherapy segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$173.0 Million While China is Forecast to Grow at 8.4% CAGR

The Ewing Sarcoma market in the U.S. is estimated at US$173.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$173.3 Million by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Ewing Sarcoma Market - Key Trends & Drivers Summarized

How Are Advancements in Diagnostic Imaging Transforming the Ewing Sarcoma Landscape?

The Ewing sarcoma market has witnessed considerable evolution in diagnostic capabilities, with imaging technology playing a pivotal role in detecting, staging, and monitoring disease progression. Positron emission tomography (PET), magnetic resonance imaging (MRI), and computed tomography (CT) have become instrumental in differentiating Ewing sarcoma from other small round cell tumors. The enhanced spatial resolution of MRI has made it the imaging modality of choice for evaluating primary tumors, especially in areas like the pelvis and axial skeleton. More recently, diffusion-weighted MRI and dynamic contrast-enhanced imaging have improved the assessment of therapeutic response, facilitating early intervention and treatment modification.

In parallel, artificial intelligence (AI)-driven image analysis platforms are gaining traction. These platforms are being integrated into hospital diagnostic systems to improve accuracy in tumor margin delineation and metastatic lesion identification. Such tools are especially relevant given the tumor's predilection for early metastasis, often to the lungs and bone marrow. The fusion of radiomics and genomics is also showing promise, with emerging models capable of predicting EWSR1 translocations, which are a defining genetic hallmark of the disease. This diagnostic evolution is driving early detection and stratified treatment decisions, ultimately improving prognosis.

What Role Do Molecular and Targeted Therapies Play in Shaping the Ewing Sarcoma Treatment Pipeline?

Traditional treatment approaches for Ewing sarcoma have long revolved around a combination of chemotherapy, surgery, and radiotherapy. However, with a stagnation in survival rates for relapsed or metastatic disease, the development pipeline has increasingly shifted toward molecularly targeted and immunotherapeutic strategies. Novel agents are now being designed to inhibit EWS-FLI1 transcription factor activity, a fusion oncoprotein resulting from EWSR1 gene rearrangement. Small molecule inhibitors targeting RNA helicase A, LSD1, and epigenetic regulators like EZH2 are in early-phase trials, aiming to directly suppress oncogenic transcription programs.

Furthermore, immunotherapeutic approaches are advancing in parallel, particularly the development of engineered T-cell therapies, such as TCR-T and CAR-T cells targeting surface proteins like CD99. Challenges with tumor microenvironment immunosuppression are being addressed through combination regimens involving checkpoint inhibitors and cytokine modulators. Bispecific antibodies and cancer vaccines are also under exploration, with some early-stage candidates demonstrating disease stabilization in refractory cases. These therapeutic innovations are gradually moving from preclinical proof-of-concept to clinical translation, especially with increasing collaboration between research institutions and oncology biotech firms.

How Is the Global Treatment Ecosystem for Ewing Sarcoma Evolving Across Regions?

The global landscape of Ewing sarcoma care varies widely depending on healthcare infrastructure, access to oncology diagnostics, and funding for rare disease treatments. In high-income regions such as North America and Western Europe, comprehensive multidisciplinary care and access to clinical trials are relatively robust. Specialized sarcoma centers offer advanced genomic sequencing and multimodal treatment regimens. Additionally, data from longitudinal patient registries and biobanks are being used to refine personalized therapy strategies and post-treatment monitoring.

In contrast, emerging economies in Asia-Pacific and Latin America face disparities in early diagnosis, treatment availability, and supportive care services. Delayed access to molecular diagnostics often leads to advanced-stage detection, which negatively impacts survival outcomes. However, public health programs and international collaborations are starting to bridge these gaps. Institutions in countries like India and Brazil are increasingly participating in global trials and adopting standardized treatment protocols. Portable imaging solutions and cloud-based health informatics are also being leveraged to improve rural outreach. These efforts reflect a growing recognition of rare pediatric oncology as a global health priority.

What Are the Key Factors Fueling Momentum in the Ewing Sarcoma Market?

The growth in the Ewing sarcoma market is driven by several factors including technological advancements in imaging and molecular diagnostics, ongoing drug development pipelines targeting fusion proteins, and a more robust clinical trial ecosystem. The rising incidence of bone sarcomas in pediatric and adolescent populations, especially in certain geographies, is heightening the focus on early screening and specialist care infrastructure. Increased advocacy and funding for rare pediatric cancers are also pushing pharmaceutical innovation, with orphan drug designations accelerating regulatory approvals and commercial viability.

Another major driver is the growing collaboration between academia, biotech startups, and global cancer consortiums. These networks enable real-time data sharing, biospecimen exchange, and multicenter clinical trials that reduce the research-to-market timeline for novel therapeutics. In addition, the adoption of digital pathology, electronic health records, and AI-based prognostic tools is streamlining clinical decision-making and fostering outcome-based treatment planning. As precision oncology becomes central to rare cancer management, the demand for integrated care models and biologically informed therapies continues to expand, propelling the overall market outlook for Ewing sarcoma solutions.

SCOPE OF STUDY:

The report analyzes the Ewing Sarcoma market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy Type (Combination Therapy, Monotherapy); Diagnostics Type (MRI Scan, CT Scan, Blood Tests, Biopsy of the Bone Marrow); End-Use (Hospitals End-Use, Specialty Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â